Updates in the pathophysiological mechanisms of Parkinson’s disease: Emerging role of bone marrow mesenchymal stem cells

Table 1 Effect of treatment with bone marrow derived mesenchymal stem cells on serum transforming growth factor beta-1 and monocyte chemoattractant protein-1 levels in Parkinson’s disease model

	TGF-β1 (pg/mL)	MCP-1 (pg/mL)
Ovariectomized control	481.5 ± 7.5	88.1 ± 0.9
PD untreated	691.2 ± 8.0a	112.1 ± 1.9a
PD + BM-MSCs	489.7 ± 13.0c	89.6 ± 2.0c

Data are represented as mean ± SE of 8 rats/group.

^aSignificant change at P < 0.05 in comparison with the ovariectomized control group;

^cSignificant change at P < 0.05 in comparison with the untreated PD group. PD: Parkinson’s disease; BM-MSCs: Bone marrow derived mesenchymal stem cells; TGF-β1: Transforming growth factor beta-1; MCP-1: Monocyte chemoattractant protein-1.